Table 4.
MS patients and control groups IgG and IgM antibody titers according to disease severity
| Mild severity COVID-19 n (%)/mean ± SD; median (min–max) |
Medium–serious severity COVID-19 n (%)/mean ± SD; median (min–max) |
p | |
|---|---|---|---|
| MS | 12 (70.16) | 5 (29.84) | – |
| Disease type |
11 1 |
2 3 |
– |
|
RRMS SPMS | |||
| Age | 37.25 ± 8.22; 38.5 (23–50) | 42.60 ± 4.82;41(39–51) | 0.139 |
| MS disease duration; years | 9.75 ± 4.88; 10.50 (2–17) | 10.20 ± 8.43;6(2–22) | 1 |
| EDSS | 1.95 ± 1.05; 1.75 (1–4) | 3.30 ± 1.15; 3.5 (1.5–4.5) | 0.036 |
| ARR | 0.60 ± 0.52; 0.51 (0.1–2) | 0.58 ± 0.28; 0.6 (0.20–1) | 0.791 |
| IgM | 2.15 ± 2.81; 0.39 (0–8.28) | 5.42 ± 4.32; 3.98 (0–10.31) | 0.225 |
| IgG | 1.84 ± 2.31; 0.69 (0–7.07) | 4.58 ± 4.15; 3.43 (0.06–11.14) | 0.206 |
| Control | |||
| IgM | 2.87 ± 2.75; 2.38 (0.02–9.06) | 4.24 ± 3.10; 2.36 (1.68–8.76) | 0.562 |
| IgG | 4.05 ± 2.98; 3.77(0.19–9.90) | 6.45 ± 3.51; 6.83 (2.66–10.66) | 0.225 |
| Total | 24 | 10 | |
| IgM | 2.51 ± 2.74; 1.74 (0–9.06) | 4.83 ± 3.60; 3.72 (0–10.31) | 0.076 |
| IgG | 2.94 ± 2.84; 2.31 (0–9.90) | 5.52 ± 3.76; 4.50 (0.06–11.14) | 0.067 |
MS multiple sclerosis, RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, ARR annual relapse rate